Oppenheimer raised the firm’s price target on HCA Healthcare (HCA) to $500 from $400 and keeps an Outperform rating on the shares. The firm notes the company reported strong Q3 results, driven by revenue-per-adjusted admission, largely due to outsized tailwinds from state supplemental payments, along with other factors, which implies high single-digit growth for Q4 2025 after adjusting for the moving parts from supp. payments and the hurricanes from last year.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HCA:
- HCA Healthcare price target raised to $505 from $475 at Mizuho
- HCA Healthcare: Hold Rating Amid Limited Growth Potential and Policy Uncertainties
- HCA Healthcare price target raised to $475 from $465 at KeyBanc
- HCA Healthcare: Strong Financial Performance and Strategic Growth Drive Buy Rating
- HCA Healthcare Reports Strong Q3 Earnings Growth